Wednesday, March 9, 2011

Dynavax Technologies loses $15M in Q4, $57M in 2010

Vaccine and drug business Dynavax Technologies Corp. lost $15.1 million in the fourth quarter and $57.3 million in 2010.
The Berkeley business (NASDAQ: DVAX), which is developing a hepatitis B vaccine and a so-called “universal” flu vaccine, lost $30.2 million a year ago in the fourth quarter ended December.

No comments:

Post a Comment

Post a Comment